

## REFERENCES

- Agarwal, S., Fulgoni, V.L. and Lieberman, H.R. (2015) 'Assessing alcohol intake & its dose-dependent effects on liver enzymes by 24-h recall and questionnaire using NHANES 2001-2010 data', *Nutrition Journal*, 15(1), p. 62. doi:10.1186/s12937-016-0180-y.
- Ahmed Mohammed, H.F. and Roberts, L.R. (2017) 'Should AFP (or any biomarkers) be used for HCC surveillance?', *Curr. Hepatol. Rep.*, 16(2), pp. 137–145.
- Ali, S., Nazeer, A. and Tipu, I. (2019) 'The Correlation between Alpha-fetoprotein and Liver Function Tests', *BioScientific Review*, 01(04), pp. 10–19. doi: 10.32350/BSR.0104.02.
- Allenson, K. *et al.* (2020) 'Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index', *Journal of gastrointestinal oncology*, 11(2), pp. 291–297. doi:10.21037/jgo.2018.11.01.
- Aprilicia, G. *et al.* (2021) 'Evaluasi Perbandingan Serum Alfa-Fetoprotein pada Pasien Karsinoma Hepatoseluler dengan Etiologi Non-Viral', *Jurnal Penyakit Dalam Indonesia*, 8(1), p. 37. doi: 10.7454/jpdi.v8i1.566.
- Ashtari, S. *et al.* (2015) 'Hepatocellular carcinoma in Asia: Prevention strategy and planning', *World J. Hepatol.*, 7(12), pp. 1708–1717.
- Assinger, A. (2014) 'Platelets and infection - an emerging role of platelets in viral infection', *Frontiers in Immunology*, 5, p. 649. doi:10.3389/fimmu.2014.00649.
- Attwa, M.H. and El-Etreby, S.A. (2015) 'Guide for diagnosis and treatment of hepatocellular carcinoma', *World journal of hepatology*, 7(12), pp. 1632–1651. doi:10.4254/wjh.v7.i12.1632.
- Aulbach, A.D. and Amuzie, C.J. (2017) 'Chapter 17 - Biomarkers in Nonclinical Drug Development', in Faqi, A.S. (ed.) *A Comprehensive Guide to Toxicology in Nonclinical Drug Development (Second Edition)*. Second Edition. Boston: Academic Press, pp. 447–471. doi:https://doi.org/10.1016/B978-0-12-803620-4.00017-7.
- Bakula, A. and Dadalski, M. (2015) 'AST-to-platelet ratio index (APRI) as marker in liver disease', in *Biomarkers in Disease: Methods, Discoveries and Applications*. Dordrecht: Springer Netherlands (Exposure and health), pp. 1–16.
- Ball, D., Rose, E. and Alpert, E. (1992) 'Alpha-Fetoprotein Levels in Normal Adults', *The American Journal of the Medical Sciences*, 303(3), pp. 157–159. doi:10.1097/00000441-199203000-00004.
- Barcena-Varela, M. and Lujambio, A. (2021) 'The Endless Sources of Hepatocellular Carcinoma Heterogeneity', *Cancers*, 13(11), p. 2621. doi:10.3390/cancers13112621.
- Bialecki, E.S. and Di Bisceglie, A.M. (2005) 'Diagnosis of hepatocellular carcinoma', *HPB: the official journal of the International Hepato Pancreato Biliary Association*, 7(1), pp. 26–34. doi:10.1080/13651820410024049.

- Bray, F. *et al.* (2024) ‘Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries’, *CA: A Cancer Journal for Clinicians*, 74(3), pp. 229–263. doi:<https://doi.org/10.3322/caac.21834>.
- Carr, B.I. (2016) *Hepatocellular Carcinoma: Diagnosis and Treatment*. 3rd ed, pp. 3–442. Springer Nature. doi: 10.1007/978-3-319-34214-6.
- Carr, B.I. and Guerra, V. (2016) ‘A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels’, *Oncology*, 90(4), pp. 215–220.
- Chiang, C.-J. *et al.* (2013) ‘Thirty-Year Outcomes of the National Hepatitis B Immunization Program in Taiwan’, *JAMA*, 310(9), pp. 974–976. doi:10.1001/jama.2013.276701.
- Chidambaranathan-Reghupaty, S., Fisher, P.B. and Sarkar, D. (2021) ‘Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification’, *Adv. Cancer Res.*, 149, pp. 1–61.
- Chun, S. *et al.* (2015) ‘Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas’, *Annals of Hepatology*, 14(6), pp. 881–887. doi:10.5604/16652681.1171776.
- Chung, W. and Kim, H. (2024) ‘The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review’, *The Ewha Medical Journal*, 47(4). doi:10.12771/emj.2024.e58.
- Dhamija, E., Paul, S.B. and Kedia, S. (2019) ‘Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern’, *Indian J. Med. Res.*, 149(1), pp. 9–17.
- Farazi, P.A. and DePinho, R.A. (2006) ‘Hepatocellular carcinoma pathogenesis: from genes to environment’, *Nature Reviews Cancer*, 6(9), pp. 674–687. doi:10.1038/nrc1934.
- Feo, F. *et al.* (2006) ‘Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition’, *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, 1765(2), pp. 126–147. doi:<https://doi.org/10.1016/j.bbcan.2005.08.007>.
- Ferlay, J. (2024) *Global Cancer Observatory: Cancer Today*. Lyon, France.
- Fu, C.-C. *et al.* (2023) ‘The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels’, *Journal of the Formosan Medical Association*, 122(7), pp. 593–602. doi:<https://doi.org/10.1016/j.jfma.2022.11.006>.
- Fu, C.-X. *et al.* (2023) ‘Diagnostic efficacy and possible underlying mechanisms of noninvasive clinical markers in hepatocellular carcinoma’, *J. Clin. Transl. Hepatol.*, 11(4), pp. 889–898.
- Fujioka, M. *et al.* (2001) ‘Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma’, *Hepatology*, 34(6), pp. 1128–1134.
- Ganne-Carrié, N. and Nahon, P. (2019) ‘Hepatocellular carcinoma in the setting of alcohol-related liver disease’, *Journal of Hepatology*, 70(2), pp. 284–293. doi:<https://doi.org/10.1016/j.jhep.2018.10.008>.

- Hamid *et al.* (2013) 'Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention (Review)', *Oncol Lett*, 5(4), pp. 1087–1092.
- Han, J.-H. *et al.* (2022) 'Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes', *Journal of Clinical Medicine*, 12(1), p. 310. Doi:10.3390/jcm12010310.
- Hann, H. *et al.* (2015) 'Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection', *Journal of Gastroenterology and Hepatology*, 30(1), pp. 131–138.
- Hasan, I. and Loho, I.M. (2017) 'Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati', in *Perhimpunan Peneliti Hati Indonesia*. Jakarta.
- Hsu, C.-Y. *et al.* (2015) 'Using serum  $\alpha$ -fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff?', *PLoS One*, 10(3), p. e0118825.
- Hu, X. *et al.* (2022) 'The landscape of alpha fetoprotein in hepatocellular carcinoma: Where are we?', *Int. J. Biol. Sci.*, 18(2), pp. 536–551.
- Jain, P. *et al.* (2015) 'Evaluation of Aspartate aminotransferase-to-platelet ratio index as a non-invasive marker for liver cirrhosis', *Journal of clinical and diagnostic research: JCDR*, 9(11), pp. OC22-4. doi:10.7860/JCDR/2015/13944.6814.
- Johnson, P. (1999) 'Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma', *J. Gastroenterol. Hepatol.*, 14(5s), pp. S32–S36.
- Kim, D.Y. (2024) 'Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide', *J. Liver Canc.*, 24(1), pp. 62–70.
- Lai, Q. *et al.* (2019) 'Platelets and hepatocellular cancer: Bridging the bench to the clinics', *Cancers (Basel)*, 11(10), p. 1568.
- Lee, K. *et al.* (2016) 'Prediction of the risk of hepatocellular carcinoma in chronic hepatitis C patients after sustained virological response by aspartate aminotransferase to platelet ratio index', *Gut and liver*, 10(5), pp. 796–802. doi:10.5009/gnl15368.
- Lee, Y.-T. *et al.* (2021) 'Diagnostic criteria and LI-RADS for hepatocellular carcinoma', *Clin. Liver Dis. (Hoboken)*, 17(6), pp. 409–413.
- Lehrich, B.M., Zhang, J. and Monga Satdarshan P and Dhanasekaran, R. (2024) 'Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma', *J. Hepatol.*, 80(3), pp. 515–530.
- Liu, Y. *et al.* (2014) 'Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B', *BMC Gastroenterology*, 14(1).
- Liu, Y. and Liu, L. (2022) 'Changes in the epidemiology of hepatocellular carcinoma in Asia', *Cancers (Basel)*, 14(18), p. 4473.
- Loaeza-del-Castillo, A. *et al.* (2008) 'AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis: Original Article', *Annals of Hepatology*, 7(4), pp. 350–357. doi: 10.1016/S1665-2681(19)31836-8.
- Loomba, R. *et al.* (2013) 'Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident

- hepatocellular carcinoma', *Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association*, 11(12), pp. 1636-45.e1-3. doi:10.1016/j.cgh.2013.04.043.
- Ma, W.-J., Wang, H.-Y. and Teng, L.-S. (2013) 'Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy', *World J. Surg. Oncol.*, 11(1), p. 212.
- Matsushita, H. and Takaki, A. (2019) 'Alcohol and hepatocellular carcinoma', *BMJ Open Gastroenterology*, 6(1). doi:10.1136/bmjgast-2018-000260.
- Mitsuhashi, N. *et al.* (2008) 'Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma', *J. Gastroenterol. Hepatol.*, 23(7 Pt 2), pp. e189-97.
- Mo, Q. *et al.* (2022) 'Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy', *Frontiers in Oncology*, Volume 12-2022. doi:10.3389/fonc.2022.876900.
- Omata, M. *et al.* (2017) 'Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update', *Hepatology international*, 11(4), pp. 317-370. doi:10.1007/s12072-017-9799-9.
- Pavlovic, N. *et al.* (2019) 'Platelets as key factors in hepatocellular carcinoma', *Cancers (Basel)*, 11(7), p. 1022.
- Qin, S. *et al.* (2024) 'Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study', *Frontiers in Genetics*, Volume 14-2023. doi:10.3389/fgene.2023.1260352.
- Safri, F. *et al.* (2024) 'Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications', *Cancer Gene Therapy*, 31(8), pp. 1105-1112. doi.org:10.1038/s41417-024-00764-w.
- Samocha-Bonet, D. *et al.* (2008) 'Platelet counts and platelet activation markers in obese subjects', *Mediators of Inflammation*, 2008, p. 834153. doi: 10.1155/2008/834153.
- Seo, S.I. *et al.* (2015) 'Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma', *World J. Gastroenterol.*, 21(13), pp. 3928-3935.
- Singal, A.G. *et al.* (2012) 'Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis', *Cancer Epidemiol. Biomarkers Prev.*, 21(5), pp. 793-799.
- Singal, A.G. *et al.* (2023) 'AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma', *Hepatology*, 78(6), pp. 1922-1965.
- Song, P.-P. *et al.* (2016) 'Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma', *World J. Gastroenterol.*, 22(1), pp. 262-274.
- Su, T.-H. *et al.* (2022) 'Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis', *Journal of the Formosan Medical Association*, 121(3), pp. 703-711. doi:https://doi.org/10.1016/j.jfma.2021.08.003.

- Suresh, D., Srinivas, A.N. and Kumar, D.P. (2020) 'Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease', *Frontiers in Oncology*, Volume 10-2020. doi:10.3389/fonc.2020.601710.
- Tateishi, R. *et al.* (2008) 'Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review', *Hepatol. Int.*, 2(1), pp. 17–30.
- Tian, S. *et al.* (2023) 'Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma', *J. Clin. Lab. Anal.*, 37(1), p. e24823.
- Toh, M.R. *et al.* (2023) 'Global epidemiology and genetics of hepatocellular carcinoma', *Gastroenterology*, 164(5), pp. 766–782.
- Tuong, T.T.K. and Duc, N.M. (2018) 'The Role Of ARFI And APRI In Diagnosis Of Liver Fibrosis On Patients With Common Chronic Liver Diseases', *Imaging in Medicine*, 10(5).
- Turshudzhyan, A. and Wu, G.Y. (2022) 'Persistently rising alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A review', *J. Clin. Transl. Hepatol.*, 10(1), pp. 159–163.
- Wai, C.-T. *et al.* (2003) 'A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C', *Hepatology*, 38(2), pp. 518–526.
- Wang, Y. *et al.* (2023) 'Elevated Serum Alpha-fetoprotein Levels in Non-alcoholic Steatohepatitis: Possible Molecular Mechanisms and Potential Clinical Significance', *Gene Expression*, 22(2), pp. 135–140.
- Wong, R.J., Ahmed, A. and Gish, R.G. (2015) 'Elevated Alpha-Fetoprotein: Differential Diagnosis - Hepatocellular Carcinoma and Other Disorders', *Clinics in Liver Disease*, 19(2), pp. 309–323. doi:10.1016/j.cld.2015.01.005.
- Yang, J. *et al.* (2022) 'The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels', *Cancer Medicine*, 11(5), pp. 1357–1370. doi:10.1002/cam4.4530.
- Yang, T.-H. *et al.* (2023) 'Genetic susceptibility to hepatocellular carcinoma in patients with chronic hepatitis virus infection', *Viruses*, 15(2).
- Yazdanpanah, F. *et al.* (2024) 'Measures for response assessment in HCC treatment', *Hepatoma Research* [Preprint].
- Zanetto, A. *et al.* (2021) 'Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis', *Cancers (Basel)*, 13(5), p. 1150.
- Zhang, C.-H. *et al.* (2022) 'Changing epidemiology of hepatocellular carcinoma in Asia', *Liver Int.*, 42(9), pp. 2029–2041.
- Zhang, J. *et al.* (2020) 'The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis', *PLoS One*, 15(2), p. e0228857.
- Zhang, X. *et al.* (2021) 'Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies', *Frontiers in Medicine*, Volume 8-2021. doi:10.3389/fmed.2021.756210.